公开(公告)号：US20230134307A1

公开(公告)日：2023-05-04

申请号：US18087302

申请日：2022-12-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuhei IKEDA ,  Makoto KAMATA ,  Yuya OGURO ,  Jumpei AIDA ,  Taisuke TAWARAISHI ,  Takeshi WAKABAYASHI ,  Norio OYABU ,  Atsuko OCHIDA ,  Kouichi IWANAGA ,  Satoshi YAMAMOTO ,  Masataka MURAKAMI ,  Minoru NAKAMURA ,  Fumie YAMAGUCHI ,  Takafumi YUKAWA

IPC: C07D207/263 ,  A61P25/18 ,  C07D401/06

Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.

公开(公告)号：US20240309016A1

公开(公告)日：2024-09-19

申请号：US18606857

申请日：2024-03-15

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Mitsunori KONO ,  Yusuke SASAKI ,  Yuya OGURO ,  Zenichi IKEDA ,  Osamu KUBO ,  Masaki SETO ,  Toru YAMASHITA ,  Makoto KAMATA ,  Kenjiro SATO ,  Matthew Thomas REYNOLDS ,  Kazuaki TAKAMI ,  Asato KINA ,  Takafumi YUKAWA ,  Minoru NAKAMURA ,  Taku KAMEI ,  Hiroyuki KAKEI ,  Fumie YAMAGUCHI ,  Tomohiro OHASHI ,  Keiko KAKEGAWA ,  Takuto KOJIMA ,  Florian PÜNNER ,  Masataka MURAKAMI ,  Takahiko TANIGUCHI ,  Tatsuki KOIKE ,  Yuichi KAJITA ,  Yuhei MIYANOHANA ,  Kohei TAKEUCHI ,  Yoshiteru ITO ,  Norihito TOKUNAGA ,  Yasushi HATTORI ,  Eiji KIMURA ,  Martin Alexander PAWLICZEK ,  Marilena PIRA ,  Shuhei IKEDA ,  Noriyuki TEZUKA ,  Yoshikazu WATANABE ,  Kevin CURRAN ,  Nicolle DOERING ,  Maria HOPKINS ,  Ben JOHNSON ,  Andre KIRYANOV ,  Jon LAM ,  Sean MURPHY ,  Natasha O'ROURKE ,  Holly REICHARD ,  Paul TANIS ,  Yunlong ZHANG

IPC: C07D498/14 ,  A61K31/407 ,  A61K31/437 ,  A61P25/26 ,  C07D498/04

CPC classification number: C07D498/14 ,  A61K31/407 ,  A61K31/437 ,  A61P25/26 ,  C07D498/04

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20230348435A1

公开(公告)日：2023-11-02

申请号：US17999505

申请日：2021-05-20

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tomoaki HASUI ,  Satoshi MIKAMI ,  Toru YAMASHITA ,  Shinji NAKAMURA ,  Shinji MORIMOTO ,  Toshihiro IMAEDA ,  Kazuaki TAKAMI ,  Masaki DAINI ,  Hiroyuki KAKEI ,  Minoru NAKAMURA ,  Fumie YAMAGUCHI ,  Chunxiang WANG ,  Sachie TAKASHIMA ,  Shogo HASHIZUME

IPC: C07D403/06 ,  A61K45/06 ,  C07D413/14 ,  C07D403/14 ,  C07D401/14 ,  C07D405/14

CPC classification number: C07D403/06 ,  A61K45/06 ,  C07D413/14 ,  C07D403/14 ,  C07D401/14 ,  C07D405/14

Abstract: The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 1-(OH-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 100 to page 143; examples 1 to 167; test examples 1 and 2; tables 1 to 4).

公开(公告)号：US20220089525A1

公开(公告)日：2022-03-24

申请号：US17310164

申请日：2020-01-23

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yuya OGURO ,  Makoto KAMATA ,  Satoshi MIKAMI ,  Shinji MORIMOTO ,  Sachie TAKASHIMA ,  Masaki DAINI ,  Osamu KUBO ,  Fumiaki KIKUCHI ,  Akinori TOITA ,  Florian PUENNER ,  Takahito KASAHARA ,  Masataka MURAKAMI ,  Shuhei IKEDA ,  Fumie YAMAGUCHI ,  Minoru NAKAMURA ,  Takafumi YUKAWA

IPC: C07C255/60 ,  C07D213/82 ,  C07D401/12 ,  C07D409/12 ,  A61P25/06 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00

Abstract: A heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like is provided. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US20240217957A1

公开(公告)日：2024-07-04

申请号：US18522917

申请日：2023-11-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Asato KINA ,  Zenichi IKEDA ,  Mitsunori KONO ,  Yuya OGURO ,  Osamu KUBO ,  Toru YAMASHITA ,  Kazuaki TAKAMI ,  Takafumi YUKAWA ,  Masaki SETO ,  Makoto KAMATA ,  Kenjiro SATO ,  Masataka MURAKAMI ,  Yusuke SASAKI ,  Matthew Thomas REYNOLDS ,  Minoru NAKAMURA ,  Taku KAMEI ,  Hiroyuki KAKEI ,  Fumie YAMAGUCHI ,  Tomohiro OHASHI ,  Takuto KOJIMA ,  Keiko KAKEGAWA ,  Florian PÜNNER ,  Shinji NAKAMURA ,  Nao MORISHITA ,  Tadashi HIDAKA ,  Sachie TAKASHIMA ,  Takahiko TANIGUCHI

IPC: C07D413/04 ,  A61P25/00 ,  C07D413/14

CPC classification number: C07D413/04 ,  A61P25/00 ,  C07D413/14

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. Provided is a compound of formula (I):




wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20230357220A1

公开(公告)日：2023-11-09

申请号：US17999514

申请日：2021-05-20

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tomoaki HASUI ,  Satoshi MIKAMI, JR. ,  Toru YAMASHITA ,  Shinji NAKAMURA ,  Shinji MORIMOTO ,  Toshihiro IMAEDA ,  Kazuaki TAKAMI ,  Masaki DAINI ,  Hiroyuki KAKEI ,  Minoru NAKAMURA ,  Fumie YAMAGUCHI ,  Chunxiang WANG ,  Sachie TAKASHIMA ,  Makoto KAMATA ,  Yuya OGURO ,  Shuhei IKEDA

IPC: C07D413/14 ,  C07D405/14 ,  C07D401/14

CPC classification number: C07D413/14 ,  C07D401/14 ,  C07D405/14

Abstract: Abstract: The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer’s disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).

公开(公告)号：US20230150934A1

公开(公告)日：2023-05-18

申请号：US18087233

申请日：2022-12-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuhei IKEDA ,  Makoto KAMATA ,  Yuya OGURO ,  Jumpei AIDA ,  Taisuke TAWARAISHI ,  Takeshi WAKABAYASHI ,  Norio OYABU ,  Atsuko OCHIDA ,  Kouichi IWANAGA ,  Satoshi YAMAMOTO ,  Masataka MURAKAMI ,  Minoru NAKAMURA ,  Fumie YAMAGUCHI ,  Takafumi YUKAWA

IPC: C07D207/263 ,  A61P25/18 ,  C07D401/06

CPC classification number: C07D207/263 ,  A61P25/18 ,  C07D401/06

Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.

公开(公告)号：US20230002318A1

公开(公告)日：2023-01-05

申请号：US17755907

申请日：2020-11-12

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuhei IKEDA ,  Makoto KAMATA ,  Yuya OGURO ,  Jumpei AIDA ,  Taisuke TAWARAISHI ,  Takeshi WAKABAYASHI ,  Norio OYABU ,  Atsuko OCHIDA ,  Kouichi IWANAGA ,  Satoshi YAMAMOTO ,  Masataka MURAKAMI ,  Minoru NAKAMURA ,  Fumie YAMAGUCHI ,  Takafumi YUKAWA

IPC: C07D207/263 ,  C07D401/06 ,  A61P25/18

Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.